PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC

Condition:   Head and Neck Cancer
Interventions:   Diagnostic Test: PD-L1 imaging;   Drug: Durvalumab
Sponsors:   Radboud University;   AstraZeneca
Not yet recruiting

http://bit.ly/2D9Ywwy